- The Japanese Ministry of Health, Labour and Welfare grants Orphan Drug status to Alexion Pharmaceuticals' (NASDAQ:ALXN) Soliris (eculizumab) for the treatment of patents with neuromyelitis optica, a life-threatening ultra-rare neurologic disorder.
- The Japanese regulator grants Orphan Drug status to medicines that treat diseases afflicting less than 50K people in Japan. Among the benefits is a 10-year period of market exclusivity if approved.
Soliris an Orphan Drug in Japan for neuromyelitis optica
Recommended For You
More Trending News
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ALXN | - | - |
Alexion Pharmaceuticals, Inc. |